SELLAS Life Sciences (SLS) Accounts Payables (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Accounts Payables data on file, last reported at $3.6 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 3.27% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $3.6 million, a 3.27% decrease from a year earlier, with the FY2025 full-year figure at $2.9 million, down 15.77% from the prior year.
• Accounts Payables for Q1 2026 stood at $3.6 million, up from $2.9 million in the prior quarter.
• Over the last five years, Accounts Payables for SLS reached as high as $7.4 million in Q1 2024 and fell as low as $2.1 million in Q3 2022.
• Historically, Accounts Payables has averaged $3.9 million across 5 years, with a median of $3.5 million in 2024.
• Across the five-year window, Accounts Payables soared 139.01% in 2024 and slumped 49.31% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $3.4 million in 2022, then soared by 67.98% to $5.6 million in 2023, then slumped by 37.93% to $3.5 million in 2024, then decreased by 15.77% to $2.9 million in 2025, then gained by 23.24% to $3.6 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $3.6 million in Q1 2026, $2.9 million in Q4 2025, and $2.3 million in Q3 2025.